Trials / Completed
CompletedNCT05533294
Study of ARO-RAGE in Healthy Subjects
A Phase 1 Study Evaluating the Effects of ARO-RAGE Injection for Subcutaneous Administration in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 43 (actual)
- Sponsor
- Arrowhead Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single- and multiple-ascending doses of ARO-RAGE Injection in normal healthy volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ARO-RAGE Injection | ARO-RAGE injection for sc administration |
| DRUG | Placebo | normal saline (0.9% NaCl) by sc injection |
Timeline
- Start date
- 2022-11-29
- Primary completion
- 2024-02-08
- Completion
- 2024-02-08
- First posted
- 2022-09-09
- Last updated
- 2024-03-29
Locations
1 site across 1 country: New Zealand
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05533294. Inclusion in this directory is not an endorsement.